LeMaitre Vascular, Inc. (NASDAQ:LMAT – Get Free Report) has received an average recommendation of “Hold” from the nine analysts that are covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $110.60.
LMAT has been the topic of several research reports. Zacks Research lowered LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Wall Street Zen downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Weiss Ratings raised shares of LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, October 8th. Citigroup restated a “market outperform” rating on shares of LeMaitre Vascular in a research note on Tuesday, July 21st. Finally, Wells Fargo & Company lowered their price objective on LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating for the company in a research report on Wednesday, August 5th.
Get Our Latest Analysis on LMAT
Institutional Trading of LeMaitre Vascular
Institutional investors and hedge funds have recently bought and sold shares of the business. Sound Income Strategies LLC lifted its position in LeMaitre Vascular by 425.6% during the 1st quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 183 shares during the period. Catalyst Capital Advisors LLC purchased a new stake in LeMaitre Vascular in the 1st quarter valued at approximately $32,000. Nykredit A S acquired a new position in LeMaitre Vascular during the 2nd quarter worth approximately $82,000. Northwestern Mutual Wealth Management Co. purchased a new position in shares of LeMaitre Vascular during the 2nd quarter worth approximately $102,000. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of LeMaitre Vascular by 28.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,393 shares of the medical instruments supplier’s stock valued at $152,000 after buying an additional 308 shares during the period. Hedge funds and other institutional investors own 84.64% of the company’s stock.
LeMaitre Vascular Stock Performance
NASDAQ LMAT opened at $83.67 on Thursday. LeMaitre Vascular has a fifty-two week low of $78.22 and a fifty-two week high of $118.01. The company has a debt-to-equity ratio of 0.40, a quick ratio of 13.96 and a current ratio of 16.31. The stock’s fifty day moving average is $80.97 and its two-hundred day moving average is $93.57. The firm has a market capitalization of $1.91 billion, a P/E ratio of 29.36, a price-to-earnings-growth ratio of 2.40 and a beta of 0.48.
LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.81 by ($0.07). The firm had revenue of $70.38 million during the quarter, compared to analysts’ expectations of $71.47 million. LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.63%. The business’s quarterly revenue was up 9.6% on a year-over-year basis. During the same period last year, the company earned $0.60 EPS. On average, research analysts anticipate that LeMaitre Vascular will post 2.89 earnings per share for the current year.
LeMaitre Vascular Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Thursday, September 3rd. Stockholders of record on Thursday, August 20th were given a dividend of $0.25 per share. The ex-dividend date was Thursday, August 20th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.2%. LeMaitre Vascular’s payout ratio is 35.09%.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc is a medical device company focused on the treatment of peripheral vascular disease. The company develops, manufactures and markets products used primarily by vascular surgeons and other specialists in open vascular surgery procedures.
Its product portfolio includes biological and synthetic vascular grafts, carotid shunts, embolectomy and thrombectomy catheters, valvulotomes, vessel closure devices, vascular patches and surgical instruments. These products are designed to support procedures involving the arteries and veins, including the repair, reconstruction and treatment of diseased or obstructed blood vessels.
Founded in 1983 and headquartered in Burlington, Massachusetts, LeMaitre Vascular sells its products through a combination of direct sales personnel and distributors.
Further Reading
- Five stocks we like better than LeMaitre Vascular
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.
